Stockscreener 앱 받기
4.53
1.74%
-0.08
시간 외 거래:
4.53
전일 마감가:
$4.61
열려 있는:
$4.55
하루 거래량:
914.02K
Relative Volume:
0.46
시가총액:
$1.67B
수익:
$9.47B
순이익/손실:
$-178.00M
주가수익비율:
-9.4375
EPS:
-0.48
순현금흐름:
$1.01B
1주 성능:
+1.80%
1개월 성능:
-17.79%
6개월 성능:
-45.88%
1년 성능:
-27.98%
1일 변동 폭
$4.46
$4.56
1주일 범위
$4.46
$4.69
52주 변동 폭
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
명칭
Bausch Health Companies Inc
전화
514-744-6792
주소
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
BHC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.53 | 1.64B | 9.47B | -178.00M | 1.01B | -0.48 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-02 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | 개시 | Raymond James | Mkt Perform |
| 2023-09-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-06-13 | 재개 | JP Morgan | Overweight |
| 2021-03-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-02-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-24 | 개시 | Citigroup | Buy |
| 2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-02 | 개시 | Goldman | Neutral |
| 2019-10-25 | 개시 | Cowen | Outperform |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-08-15 | 업그레이드 | TD Securities | Hold → Buy |
| 2019-07-19 | 개시 | Wolfe Research | Outperform |
| 2019-06-11 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-01-02 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | 업그레이드 | Piper Jaffray | Underweight → Neutral |
모두보기
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
The most oversold and overbought stocks on the TSX - The Globe and Mail
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Hyperopia Treatment Market Growth, Trends & Opportunities - openPR.com
Bausch Health Elects New Board at Annual Meeting - TipRanks
Bausch Health Announces 2025 Annual Meeting of Shareholder Results - ACCESS Newswire
Bausch Health Annual Meeting: Shareholders Back Board Slate, Executive Pay, and New Stock Plan - Stock Titan
Otoplasty Market Is Booming Worldwide 2025-2032 | Allergan,Bausch Health Companies,Sientra - openPR.com
Bausch + Lomb Brief: Announcing the U.S. Launch of Zenlens CHROMA HOA scleral contact lenses - marketscreener.com
Medical Lasers Market 2025-2032: Emerging Trends, Growth - openPR.com
Oral Mucositis Market Outlook: Trends & Forecast 2024-2031 | - openPR.com
Raymond James Financial Inc. Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Mariner LLC Sells 2,340 Shares of Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing - MSN
Scar Treatment Market Detailed In New Research Report 2025 | - openPR.com
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Bausch Health shares fall 39% following InvestingPro’s overvalued warning By Investing.com - Investing.com
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens - marketscreener.com
Bausch Health (BHC) Data Highlights Reduced Rehospitalization wi - GuruFocus
Bausch Health (BHC) Data Highlights Reduced Rehospitalization with Xifaxan Use | BHC Stock News - GuruFocus
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests efficacy of Xifaxan - marketscreener.com
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - voiceofalexandria.com
Bausch Health (BHC) Target Price Reduced by Raymond James | BHC Stock News - GuruFocus
Bausch Health (BHC) Faces Revised Price Target by Raymond James | BHC Stock News - GuruFocus
Bausch Health price target cut to $8 by Raymond James - Investing.com Nigeria
Dry Eye Syndrome Treatment Market Set to Witness Significant - openPR.com
BHC: RBC Capital Raises Price Target for Bausch Health Companies | BHC Stock News - GuruFocus
Bausch Health Companies Inc (BHC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
18.36%
0.52%
자본화:
|
볼륨(24시간):